Stem cell fat grafting

Last updated
Example of breast augmentation by fat grafting Dr. Placik Chicago Breast Fat Grafting 19097.jpg
Example of breast augmentation by fat grafting

Stem cellfat grafting is autotransplantation of adipose-derived stem cells (ADSCs) extracted from fat-abundant donor sites (i.e. thigh or stomach) to other areas such as the face, breast, and hip to reconstruct the operative areas into desirable shapes. [1] ADSCs are multipotent stem cells found in adipose tissues, displaying similar differentiation potentials to bone marrow-derived mesenchymal stem cells (BM-MSCs). [2]

Contents

The discovery of ADSCs has brought great advances to the field of regenerative medicine and aesthetic procedures.Whilst the use of embryonic stem cells was reconsidered for ethical reasons, ADSCs got attention from plastic surgeons owing to their characteristics such as pluripotent differentiation potential, paracrine activities, immunomodulatory functions, and homing effect. [3]

Regardless of the numerous benefits, there are few side effects and oncology safety issues The rising investment in stem cell cosmetic therapy reflects the high expectation and demands especially in South Korea. Further research on the effectiveness of ADSCs grafting proposed that the aftermath of the therapy can be affected by the quality of stem cells and diet by fostering adequate conditions for stem cell growth and sufficient consumption of nutrients. [4]

History of stem cell plastic surgery

RECENT CONTROVERSIES IN STEM CELL RESEARCH (IA gov.gpo.fdsys.CHRG-109shrg31011) RECENT CONTROVERSIES IN STEM CELL RESEARCH (IA gov.gpo.fdsys.CHRG-109shrg31011).pdf
RECENT CONTROVERSIES IN STEM CELL RESEARCH (IA gov.gpo.fdsys.CHRG-109shrg31011)

Dr.James Thomson at the University of Wisconsin first isolated human embryonic stem cells in 1998. However, due to the ethical controversies regarding embryonic stem cells, the induced pluripotent stem cells (iPSCs) were proposed as the substitute. The remaining oncological concern of iPSCs was eased by suggesting adult stem cells as the most primary resource of regenerative medicine. [5]

History of autologous fat grafting

The first isolation of mesenchymal stem cells from the bone marrow was done by Friednstein et al. in 1986 and considered as a primary clinical stem cell source. However, the painful acquisition and low cell yield limited further research. Then Zuk et al. isolated ADSCs and found it has same potentials as BM-MSCs. Although later other stem cells were identified from different parts of the human body, ADSCs was considered to be the safest as it was the easiest stem cell to isolate and did not require cell expansion. Thus ADSCs are still used as a primary source of fat transfer therapies. [6]

The concept of autologous fat grafting was first suggested in 1893. The first report described that the adipose tissue without changing its structure was implanted to the adherent scars from osteomyelitis. The result was successful and soon widely used in different fields of aesthetic procedures such as breast augmentation and rhinoplasties. [6]

In 1978, a liposuction procedure was invented to remove the excessive fat depositions. Later, Illouz found that this procedure is the ideal supplier of fat tissue and used impurified lipoaspirate as a transplant in 1983 and Fournier proposed a reinjection technique of aspirated fat. [6]

The third period starts from 1994 when S.R. Coleman introduced the Coleman technique, which uses adipose tissue for lipids cell transfer. The lipoaspirate was centrifuged to separates the stromal vascular fraction(SVF) including ADSCs from blood, tissue, fluid, and lipids. [3] Yet, the fat cell retention rate was varied from 30% to 95%. The first theory that explains graft survival is the Cell Survival Theory, which suggests that the transfer of viable adipocytes for adequate circulation enhances the survival rate and this can be done by developing the processing and injection techniques to minimize trauma. [6]

The recent theory is the Host replacement theory that retention rate after fat grafting is determined by the ADSCs replacing adipocytes, as the successful ADSCs activation and replacement of adipocytes is related to the early death of transferred adipocytes in ischemic conditions. [6]

Mechanisms

ADSCs

Human mesenchymal stem cells Human mesenchymal stem cells.gif
Human mesenchymal stem cells

Fang et al. proposed that ADSCs are the most widely used due to the following three characteristics: their pluripotent differentiation potentials, paracrine activity and immunomodulatory function. ADSCs are one type of mesenchymal stem cells (MSCs), and they exhibit high similarities with BM-MSCs. [7] Hence, they are capable of multilineage differentiation into fats, cartilages, cardiac muscles, nerves, skins, and Skeletal muscles. They also tend to survive for a longer period with a higher proliferative capacity than other stem cells. ADSCs secret pro-angiogenic factors and anti-apoptotic factors like cytokines, chemokines, growth factors, mRNAs, and microRNAs. Then, they act on different systems where they were transplanted and regenerate cells in these transplanted systems. Moreover, as ADSCs resemble BM-MSCs, they have immunosuppressive characteristics, suppressing both innate and adaptive immune systems. However, their capacity is even stronger than BM-MSCs by secretion of immunosuppressive factors such as IL-6 and TGF-B. Additionally, they perform as immune tolerators to suppress lymphocyte proliferation; such property suggests the possibility of ADSCs for xenotransplantation. [8]

Homing effect

The homing effect refers to the engraftment of ADSCs to bone marrow endothelium owing to the arrest of ADSCs within the vasculature of a tissue. ADSCs are engrafted to the bone marrow endothelium, as they circulate across the endothelium and adhesion interactions are activated to the bone marrow endothelium. Thus, such engraftment increases the probability of long-term survival of transferred fats. The homing effect follows three main processes: rolling, adhesion, and transmigration. During the rolling, ADSCs migrate and interacts with vascular endothelial cells in bone marrow in shear-resistant and low-affinity manners. As ADSCs adhere to bone marrow endothelium, MSCs express several different molecules that increase the adhesion such as CD44 isoforms and integrins. As ADSCs transmigrate through vessels in bone marrow, interaction and signaling between stromal-derived chemokine factor -1 (SDF-1) and receptor CXCR4 is the most crucial process. [9] [10]

Isolation or expansion from fats

Mechanical+Enzymatic(ME) and mechanical methods are the most common isolation methods, although there is no standard method. [11] Accordingly, Dr. Glass and Ferretti proposed one of the ME methods which is to apply tumescent-assisted liposuction using a mechanical or ultrasound-assisted liposuction cannula. Through liposuction, the fat sample is digested by enzymatic activities of collagenase or trypsin in Dulbecco’s modified Eagle's medium (DMEM). The resultant tissue suspension undergoes incubation and agitation at around 37 °C and is filtered through a strainer to remove unnecessary debris. The cell pallet left after centrifugation is called SVF. The SVF is seeded on the plate, after the second suspension with bovine calf serum, 1% penicillin or streptomycin, and L-glutamine. The adherent properties of ADSCs on the plate allow isolation of ADSCs. [12] However, due to the inconvenience of isolating the pure ADSCs, a cell-assisted lipo-transfer (CAL) is more commonly used. CAL transforms poor ADSCs into enriched ADSCs by mixing isolate SVF and aspirated fat. [13] The efficacy of CAL was proven by the increased survival rate of autologous breast augmentation when introduced around 270ml for each breast. [14]

Complications and safety

Breast implant

Around 1.5 million women have breast implant surgeries per year. [15] Yet the side effects of the fat transplant can be severe and cause irreversible damage to the patient's body. The most well-known side effects are foreign body sensation, calcification, fat cell necrosis, capsular construction, rupture, cysts and some fat cells leaving the implanted area.

Benign calcification in breast, at high magnification Calcification in breast benign -- high mag.jpg
Benign calcification in breast, at high magnification

In most cases, calcification and cysts are the biggest threat of breast augmentation surgery. Fat stem cells failed to pick up a new blood supply will die and be removed from the body by immune cells. However, when this clearing process miss removing dead cells the cluster will lead to calcification and cysts formation. These are visible on the breast as lump sometimes and are more dangerous when these un-picked up dead cells are detected as cancer cells which disturbs accurate diagnosis of breast cancer. The calcified tissue will be diagnosed as a 'benign' cancer and not cause any harm. However, if the tissue is severely damaged the entire breast needs to be removed. Once a patient is diagnosed with calcification of breast implant, regular mammograms should be done to monitor the possible cancer development. [16]

Facial fat transfer

Gornitsky et al. from McGill University conducted a systematic review of 4577 patients who have received the facial fat transfer. The most prevalent side effects were reported like the following: asymmetry, skin irregularities, hypertrophy, prolonged edema, fat necrosis and such. [17]

Oncology safety

The homing effect may have advantages in increasing the long-term survival of transferred fat, but concerns remain for patients with post-oncologic history, specifically breast cancer. It is more alarming since breast tumors are closely located with adipose tissue, as they develop a favorable microenvironment for cancer progression through homing and migration. [18] There are cancer-associated adipocytes (CAAs) crucial for metastasis and the progression of tumors. Under normal conditions, the adipocytes are mature and they do not differentiate. However, when ADSCs migrate and circulate in blood vessels by homing properties can result in the progression of tumor growth. Furthermore, the properties of migratory cells also promote tumor growth by secretion of trophic factors such as adipokines, including FGF, ILs and IGF-binding proteins. This increases vascularisation as such oncogenic properties are unusual for other BM-MSCs or lung-derived MSDCs. [19]

Application and marketing

Stem cell market

The stem cell market has grown largely along with the increasing awareness of stem cells in regenerative medicine. The Google web search big data analysis showed that the terms “Stem cell facelift” had 197,000 outcomes and “stem cell breast augmentation" had approximately 302,000 outcomes according to the American Society of Plastic Surgeons. [20]

Nature of stem cell therapies offered across surveyed websites Nature of stem cell therapies offered across surveyed websites.png
Nature of stem cell therapies offered across surveyed websites

With the rising interest in stem cell cosmetic therapy, this figure demonstrates the content analysis on the 50 clinical websites that appeared on the Google search platform for “stem cell therapy”, “treatment” or “stem cell facelift” in November 2013. The result showed that (A) 90% of the clinics use Autologous adult stem cell. (B) 71% of clinics obtained stem cells were from patient fat. (C) 90% of procedures delivered cells through subcutaneous methods. (D) facial-anti ageing treatment was advertised the most in “stem cell” treatments as well as “stem cell breast augmentation” therapies. [21]

Case study: South Korea

The International Association of Aesthetic Plastic Surgery (ISAPS), announced the Korean plastic surgery market is estimated to be about the scale of $440 million as of 2017. It is a 1/4 of the world market, and the number of plastic surgeries per year ranked the first (13.5 per 1000 population per year). Korean stem cell markets formed a scale of $1.1 billion in 2016 and they are expected to grow to 26.67% annually by 2025 ($9.5 billion). [22] [23]

In 2017 the government invested in the bio sector for the highest proportion for new drug development (13%), and only 4% on stem cells ($112 million). CartistemTM, Inc. Medipost published successfully developed stem cell-based degenerative knee cartilage therapy and has achieved more than 10 billion sales since 2017. [22] [23]

Behind the large stem cell cosmetic therapy market size of South Korea, non-specialists practice without a licence in some clinics. According to the National Statistical Office data, the number of plastic surgeons is 1,924 in 2018, and the Korean Plastic Surgery Association estimates that non-specialists in cosmetic surgery will be about 10 times that of specialists.

Dr Shin mentioned, "There have been similar surgeries that advocate stem cell breast plastic surgery recently. When receiving stem cell breast surgery, patients need to check whether the doctor has officially proved and whether the hospital has stem cell researchers and high-quality equipment." [24]

Diet after stem cell therapy

Studies have shown that diet is closely related to stem cell proliferation and performance. Among numerous chemicals that affect the entire stem cell differentiation and settlement process, it is shown that taking extra supplements such as below can help stem cells to function better.

Related Research Articles

<span class="mw-page-title-main">Bone marrow</span> Semi-solid tissue in the spongy portions of bones

Bone marrow is a semi-solid tissue found within the spongy portions of bones. In birds and mammals, bone marrow is the primary site of new blood cell production. It is composed of hematopoietic cells, marrow adipose tissue, and supportive stromal cells. In adult humans, bone marrow is primarily located in the ribs, vertebrae, sternum, and bones of the pelvis. Bone marrow comprises approximately 5% of total body mass in healthy adult humans, such that a man weighing 73 kg (161 lbs) will have around 3.7 kg (8 lbs) of bone marrow.

<span class="mw-page-title-main">Adipose tissue</span> Loose connective tissue composed mostly by adipocytes

Adipose tissue is a loose connective tissue composed mostly of adipocytes. It also contains the stromal vascular fraction (SVF) of cells including preadipocytes, fibroblasts, vascular endothelial cells and a variety of immune cells such as adipose tissue macrophages. Its main role is to store energy in the form of lipids, although it also cushions and insulates the body.

<span class="mw-page-title-main">Adipocyte</span> Cells that primarily compose adipose tissue, specialized in storing energy as fat

Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Adipocytes are derived from mesenchymal stem cells which give rise to adipocytes through adipogenesis. In cell culture, adipocyte progenitors can also form osteoblasts, myocytes and other cell types.

<span class="mw-page-title-main">Breast augmentation</span> Surgical procedure

Breast augmentation and augmentation mammoplasty is a cosmetic surgery technique using breast-implants and fat-graft mammoplasty techniques to increase the size, change the shape, and alter the texture of the breasts. Augmentation mammoplasty is applied to correct congenital defects of the breasts and the chest wall. As an elective cosmetic surgery, primary augmentation changes the aesthetics – of size, shape, and texture – of healthy breasts.

<span class="mw-page-title-main">Cell therapy</span> Therapy in which cellular material is injected into a patient

Cell therapy is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy, or grafting stem cells to regenerate diseased tissues.

Stromal cells, or mesenchymal stromal cells, are differentiating cells found in abundance within bone marrow but can also be seen all around the body. Stromal cells can become connective tissue cells of any organ, for example in the uterine mucosa (endometrium), prostate, bone marrow, lymph node and the ovary. They are cells that support the function of the parenchymal cells of that organ. The most common stromal cells include fibroblasts and pericytes. The term stromal comes from Latin stromat-, "bed covering", and Ancient Greek στρῶμα, strôma, "bed".

<span class="mw-page-title-main">Adult stem cell</span> Multipotent stem cell in the adult body

Adult stem cells are undifferentiated cells, found throughout the body after development, that multiply by cell division to replenish dying cells and regenerate damaged tissues. Also known as somatic stem cells, they can be found in juvenile, adult animals, and humans, unlike embryonic stem cells.

Stem-cell therapy uses stem cells to treat or prevent a disease or condition. As of 2016, the only established therapy using stem cells is hematopoietic stem cell transplantation. This usually takes the form of a bone marrow transplantation, but the cells can also be derived from umbilical cord blood. Research is underway to develop various sources for stem cells as well as to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes and heart disease.

Articular cartilage, most notably that which is found in the knee joint, is generally characterized by very low friction, high wear resistance, and poor regenerative qualities. It is responsible for much of the compressive resistance and load bearing qualities of the knee joint and, without it, walking is painful to impossible. Osteoarthritis is a common condition of cartilage failure that can lead to limited range of motion, bone damage and invariably, pain. Due to a combination of acute stress and chronic fatigue, osteoarthritis directly manifests itself in a wearing away of the articular surface and, in extreme cases, bone can be exposed in the joint. Some additional examples of cartilage failure mechanisms include cellular matrix linkage rupture, chondrocyte protein synthesis inhibition, and chondrocyte apoptosis. There are several different repair options available for cartilage damage or failure.

Mesenchymal stem cells (MSCs) are multipotent cells found in multiple human adult tissues, including bone marrow, synovial tissues, and adipose tissues. Since they are derived from the mesoderm, they have been shown to differentiate into bone, cartilage, muscle, and adipose tissue. MSCs from embryonic sources have shown promise scientifically while creating significant controversy. As a result, many researchers have focused on adult stem cells, or stem cells isolated from adult humans that can be transplanted into damaged tissue.

Amniotic stem cells are the mixture of stem cells that can be obtained from the amniotic fluid as well as the amniotic membrane. They can develop into various tissue types including skin, cartilage, cardiac tissue, nerves, muscle, and bone. The cells also have potential medical applications, especially in organ regeneration.

MIRA is a multidisciplinary and complementary method for treating many chronic diseases. The MIRA Procedure is a result of combining efforts from different medical fields developed in the University of Chicago in 1992. It basically consists in medically grafting live rejuvenated tissue in the form of autologous adipose adult stem cells to a damaged organ in order to restore it and improve its function. This method is currently approved by the U.S. Food and Drug Administration (FDA).

<span class="mw-page-title-main">Mesenchymal stem cell</span> Multipotent, non-hematopoietic adult stem cells present in multiple tissues

Mesenchymal stem cells (MSCs) also known as mesenchymal stromal cells or medicinal signaling cells, are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes and adipocytes.

Adult mesenchymal stem cells are being used by researchers in the fields of regenerative medicine and tissue engineering to artificially reconstruct human tissue which has been previously damaged. Mesenchymal stem cells are able to differentiate, or mature from a less specialized cell to a more specialized cell type, to replace damaged tissues in various organs.

A Muse cell is an endogenous non-cancerous pluripotent stem cell. They reside in the connective tissue of nearly every organ including the umbilical cord, bone marrow and peripheral blood. They are collectable from commercially obtainable mesenchymal cells such as human fibroblasts, bone marrow-mesenchymal stem cells and adipose-derived stem cells. Muse cells are able to generate cells representative of all three germ layers from a single cell both spontaneously and under cytokine induction. Expression of pluripotency genes and triploblastic differentiation are self-renewable over generations. Muse cells do not undergo teratoma formation when transplanted into a host environment in vivo. This can be explained in part by their intrinsically low telomerase activity, eradicating the risk of tumorigenesis through unbridled cell proliferation. They were discovered in 2010 by Mari Dezawa and her research group. Clinical trials for acute myocardial infarction, stroke, epidermolysis bullosa, spinal cord injury, amyotrophic lateral sclerosis, acute respiratory distress syndrome (ARDS) related to novel coronavirus (SARS-CoV-2) infection, are conducted by Life Science Institute, Inc., a group company of Mitsubishi Chemical Holdings company. In february 2023, however, Mitsubishi Chemical Group decided to discontinue the development of a regenerative medicine product (CL2020) using Muse Cells. Physician-led clinical trial for neonatal hypoxic-ischemic encephalopathy was also started. The summary results of a randomized double-blind placebo-controlled clinical trial in patients with stroke was announced.

Facial Autologous Muscular Injection is also known as Fat Autograft Muscular Injection, as Autologous Fat Injection, as Micro-lipoinjection, as Fat Transfer and as Facial Autologous Mesenchymal Integration, abbreviated as FAMI. The technique is a non-incisional pan-facial rejuvenation procedure using the patient'own stem cells from fat deposits. FAMI is an Adult stem cell procedure used to address the loss of volume in the face due to aging or surgery repair in restoring facial muscles, bone surfaces and very deep fat pads. The procedure involves removing adult stem cells of fatty tissue from lower body, and refining it to be able to re-inject living adipose stem cells into specific areas of the face without incision. FAMI is an outpatient procedure and an alternative to artificial fillers, blepharoplasty or various face lifts. The procedure does not require general anesthesia and risks of an allergic reaction are minimal due to the use of the patient's own tissue used as the facial injection.

<span class="mw-page-title-main">Bone marrow adipose tissue</span>

Bone marrow adipose tissue (BMAT), sometimes referred to as marrow adipose tissue (MAT), is a type of fat deposit in bone marrow. It increases in states of low bone density -osteoporosis, anorexia nervosa/caloric restriction, skeletal unweighting such as that which occurs in space travel, and anti-diabetes therapies. BMAT decreases in anaemia, leukaemia, and hypertensive heart failure; in response to hormones such as oestrogen, leptin, and growth hormone; with exercise-induced weight loss or bariatric surgery; in response to chronic cold exposure; and in response to pharmacological agents such as bisphosphonates, teriparatide, and metformin.

<span class="mw-page-title-main">Shimon Slavin</span> Israeli professor of medicine

Shimon Slavin is an Israeli professor of medicine. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for induction of transplantation tolerance to bone marrow and donor allografts.

Craniofacial regeneration refers to the biological process by which the skull and face regrow to heal an injury. This page covers birth defects and injuries related to the craniofacial region, the mechanisms behind the regeneration, the medical application of these processes, and the scientific research conducted on this specific regeneration. This regeneration is not to be confused with tooth regeneration. Craniofacial regrowth is broadly related to the mechanisms of general bone healing.

Fat transfer, also known as fat graft, lipomodelling, or fat injections, is a surgical process in which a person's own fat is transferred from one area of the body to another area. The major aim of this procedure is to improve or augment the area that has irregularities and grooves. Carried out under either general anesthesia or local anesthesia, the technique involves 3 main stages: fat harvesting, fat processing, fat injection.

References

  1. ↑ Bellini, Elisa; Grieco, Michele; Raposio, Edoardo (10 December 2017). "The science behind autologous fat grafting". Annals of Medicine and Surgery. 24: 65–73. doi:10.1016/j.amsu.2017.11.001. PMC   5694962 . PMID   29188051.
  2. ↑ Rochette, Luc; Mazini, Loubna; Malka, Gabriel; Zeller, Marianne; Cottin, Yves; Vergely, Catherine (4 December 2020). "The Crosstalk of Adipose-Derived Stem Cells (ADSC), Oxidative Stress, and Inflammation in Protective and Adaptive Responses". International Journal of Molecular Sciences. 21 (23): 9262. doi: 10.3390/ijms21239262 . PMC   7730805 . PMID   33291664.
  3. 1 2 Simonacci, F; Bertozzi, N; Grieco, MP; Grignaffini, E; Raposio, E (August 2017). "Procedure, applications, and outcomes of autologous fat grafting". Annals of Medicine and Surgery. 20: 49–60. doi:10.1016/j.amsu.2017.06.059. PMC   5491488 . PMID   28702187.
  4. 1 2 Team, The Biotics Education. "7 Ways to Promote Stem Cell Proliferation". blog.bioticsresearch.com.
  5. ↑ Evans, Gregory R. D.; Widgerow, Alan D. (30 May 2020). "Stem cells and tissue engineering in plastic surgery: an update". Plastic and Aesthetic Research. 7: 28. doi: 10.20517/2347-9264.2019.53 . ISSN   2347-9264.
  6. 1 2 3 4 5 Varghese, Jajini; Mosahebi, Afshin (1 July 2017). "Historical Overview of Stem Cell Biology and Fat Grafting". Aesthetic Surgery Journal. 37 (suppl_3): S1–S3. doi: 10.1093/asj/sjw262 . PMID   29025211.
  7. ↑ Mazini, Loubna; Rochette, Luc; Amine, Mohamed; Malka, Gabriel (22 May 2019). "Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs)". International Journal of Molecular Sciences. 20 (10): 2523. doi: 10.3390/ijms20102523 . PMC   6566837 . PMID   31121953.
  8. ↑ Fang, Jun; Chen, Feng; Liu, Dong; Gu, Feiying; Wang, Yuezhen (6 January 2021). "Adipose tissue-derived stem cells in breast reconstruction: a brief review on biology and translation". Stem Cell Research & Therapy. 12 (1): 8. doi: 10.1186/s13287-020-01955-6 . PMC   7789635 . PMID   33407902.
  9. ↑ Zhao, Yong; Zhang, Haiyang (1 July 2016). "Update on the mechanisms of homing of adipose tissue-derived stem cells". Cytotherapy. 18 (7): 816–827. doi:10.1016/j.jcyt.2016.04.008. PMID   27260205.
  10. ↑ Liesveld, Jane L.; Sharma, Naman; Aljitawi, Omar S. (2020). "Stem cell homing: From physiology to therapeutics". Stem Cells. 38 (10): 1241–1253. doi: 10.1002/stem.3242 . PMID   32526037.
  11. ↑ Raposio, Edoardo; Simonacci, Francesco; Perrotta, Rosario E. (8 July 2017). "Adipose-derived stem cells: Comparison between two methods of isolation for clinical applications". Annals of Medicine and Surgery. 20: 87–91. doi:10.1016/j.amsu.2017.07.018. ISSN   2049-0801. PMC   5508488 . PMID   28736612.
  12. ↑ Glass, Graeme Ewan; Ferretti, Patrizia (14 March 2019). "Adipose-Derived Stem Cells in Aesthetic Surgery" (PDF). Aesthetic Surgery Journal. 39 (4): 423–438. doi: 10.1093/asj/sjy160 . PMID   29982396.
  13. ↑ Wang, Yu; Wu, Yanfei (19 October 2017). "Assessment of the clinical efficacy of cell-assisted lipotransfer and conventional fat graft: a meta-analysis based on case-control studies". Journal of Orthopaedic Surgery and Research. 12 (1): 155. doi: 10.1186/s13018-017-0645-5 . ISSN   1749-799X. PMC   5649090 . PMID   29052508.
  14. ↑ Mazini, Loubna; Ezzoubi, Mohamed; Malka, Gabriel (4 January 2021). "Overview of current adipose-derived stem cell (ADSCs) processing involved in therapeutic advancements: flow chart and regulation updates before and after COVID-19". Stem Cell Research & Therapy. 12 (1): 1. doi: 10.1186/s13287-020-02006-w . PMC   7781178 . PMID   33397467.
  15. ↑ Alotaibi, Shaikha; Hamadani, Mehdi; Al-Mansour, Mubarak; Aljurf, Mahmoud (1 March 2021). "Breast Implant-associated Anaplastic Large Cell Lymphoma". Clinical Lymphoma, Myeloma & Leukemia. 21 (3): e272–e276. doi: 10.1016/j.clml.2020.12.005 . PMID   33384263.
  16. ↑ Horton, Karen. "Why not augment the breasts with your own fat? A warning!". www.drkarenhorton.com. Dr Karen M. Horton.
  17. ↑ Gornitsky, Jordan; Viezel-Mathieu, Alex; Alnaif, Nayif; Azzi, Alain; Gilardino, Mirko (1 March 2019). "A systematic review of the effectiveness and complications of fat grafting in the facial region". JPRAS Open. 19: 87–97. doi:10.1016/j.jpra.2018.12.004. ISSN   2352-5878. PMC   7061561 . PMID   32158860.
  18. ↑ O’Halloran, Niamh; Courtney, Donald; Kerin, Michael J; Lowery, Aoife J (1 January 2017). "Adipose-Derived Stem Cells in Novel Approaches to Breast Reconstruction: Their Suitability for Tissue Engineering and Oncological Safety". Breast Cancer: Basic and Clinical Research. 11: 117822341772677. doi:10.1177/1178223417726777. PMC   5562338 . PMID   29104428.
  19. ↑ Scioli, Maria Giovanna; Storti, Gabriele; D’Amico, Federico; Gentile, Pietro; Kim, Bong-Sung; Cervelli, Valerio; Orlandi, Augusto (4 July 2019). "Adipose-Derived Stem Cells in Cancer Progression: New Perspectives and Opportunities". International Journal of Molecular Sciences. 20 (13): 3296. doi: 10.3390/ijms20133296 . PMC   6651808 . PMID   31277510.
  20. ↑ The American Society of Plastic Surgeons. "Joint ASPS & ASAPS Position Statement: Stem Cells and Fat Grafting" (PDF). Plastic surgery.
  21. ↑ McArdle, Adrian; Senarath-Yapa, Kshemendra; Walmsley, Graham G.; Hu, Michael; Atashroo, David A.; Tevlin, Ruth; Zielins, Elizabeth; Gurtner, Geoffrey C.; Wan, Derrick C.; Longaker, Michael T. (2014). "The Role of Stem Cells in Aesthetic Surgery: Fact or Fiction?". Plastic and Reconstructive Surgery. 134 (2): 193–200. doi:10.1097/PRS.0000000000000404. ISSN   0032-1052. PMC   4447486 . PMID   24732654.
  22. 1 2 Kim, Kyung Ae (1 November 2019). "연평균 17% 성장한다는데…'줄기세포' 연구 홀대?". 히트뉴스 (in Korean). HitNews.
  23. 1 2 "생명공학정책연구센터". www.bioin.or.kr.
  24. ↑ Chung, Sim Kyo (December 29, 2020). "밋밋한 가슴의 유학생, 줄기세포 가슴 성형 위해 귀국한 이유는 :: 중앙일보헬스미디어". jhealthmedia.joins.com.
  25. ↑ Godoy-Parejo, Carlos; Deng, Chunhao; Zhang, Yumeng; Liu, Weiwei; Chen, Guokai (May 2020). "Roles of vitamins in stem cells". Cellular and Molecular Life Sciences. 77 (9): 1771–1791. doi:10.1007/s00018-019-03352-6. PMID   31676963. S2CID   207828217.
  26. ↑ Cortes, Mauricio; Chen, Michael; Stachura, David; Liu, Sarah; Kwan, Wanda; Wright, Francis; Vo, Linda; Theodore, Lindsay; Esain, Virginie; Frost, Isaura; Schlaeger, Thorsten; Goessling, Wolfram; Daley, George; North, Trista (4 October 2016). "Developmental Vitamin D Availability Impacts Hematopoietic Stem Cell Production". Cell Reports. 17 (2): 458–468. doi:10.1016/j.celrep.2016.09.012. ISSN   2211-1247. PMC   5338633 . PMID   27705794.
  27. ↑ Jung, Jin Hyuk; Iwabuchi, Kumiko; Yang, Zhihong; Loeken, Mary R. (17 June 2016). "Embryonic Stem Cell Proliferation Stimulated By Altered Anabolic Metabolism From Glucose Transporter 2-Transported Glucosamine". Scientific Reports. 6 (1): 28452. Bibcode:2016NatSR...628452J. doi:10.1038/srep28452. PMC   4911601 . PMID   27311888.
  28. ↑ Mehrabani, D; Mojtahed Jaberi, F; Zakerinia, M; Hadianfard, MJ; Jalli, R; Tanideh, N; Zare, S (May 2016). "The Healing Effect of Bone Marrow-Derived Stem Cells in Knee Osteoarthritis: A Case Report". World Journal of Plastic Surgery. 5 (2): 168–74. PMC   5003953 . PMID   27579273.
  29. ↑ "Diet & Blood Sugar Levels The Effect on Stem Cells". Regen America. 2 January 2018.
  30. ↑ He, Jingjing; Kong, Desheng; Yang, Zhifen; Guo, Ruiyun; Amponsah, Asiamah Ernest; Feng, Baofeng; Zhang, Xiaolin; Zhang, Wei; Liu, Aijing; Ma, Jun; O’Brien, Timothy; Cui, Huixian (11 March 2021). "Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data". PLOS ONE. 16 (3): e0247662. Bibcode:2021PLoSO..1647662H. doi: 10.1371/journal.pone.0247662 . ISSN   1932-6203. PMC   7951834 . PMID   33705413.
  31. ↑ Lo, Ting; Ho, Jennifer H.; Yang, Muh-Hwa; Lee, Oscar K. (1 July 2011). "Glucose Reduction Prevents Replicative Senescence and Increases Mitochondrial Respiration in Human Mesenchymal Stem Cells". Cell Transplantation. 20 (6): 813–826. doi: 10.3727/096368910X539100 . ISSN   1555-3892. PMID   21054932. S2CID   30722685.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.